axinn

Awards & Recognitions

Axinn Attorneys Named to Best Lawyers 2025

Axinn is pleased to announce that eleven attorneys have been named to the 2025 list of "Best Lawyers in America" and sixteen attorneys have been named to the list of "Ones to Watch." Two attorneys have been named "Lawyer of the Year" in their individual practice areas.

Learn More \rightarrow

Intellectual Property

We recognize the significant investment our clients make in developing their products and technologies. Our nationwide team of intellectual property attorneys is dedicated to safeguarding these innovations with strategic and incisive legal counsel. Whether advising on global product launches or handling multibillion-dollar patent litigation, we are committed to protecting IP rights and fueling business growth.

Leading High-Stakes Trials & Appeals

Our first-chair trial lawyers bring extensive experience in all phases of patent and trade secret litigation, including at trial and on appeal. We have led some of the most high-profile cases in federal and state courts nationwide and regularly advocate for our clients before the International Trade Commission (ITC) and Patent Trial and Appeal Board (PTAB).

Protecting IP Portfolios

We help clients grow and protect their IP portfolios by offering strategic counseling and regulatory services, including portfolio management, IP due diligence, audits, corporate transactions, and licensing agreements. When defending innovations, we collaborate with our antitrust lawyers to ensure compliance and to safeguard our clients' market positions.

Leveraging Technical Acuity

Many of our IP attorneys hold advanced technical degrees, allowing us to adeptly represent clients across industries such as pharmaceuticals, biotechnology, medical devices, consumer products, and technology, including in matters involving standard essential patents. By combining extensive technical expertise, legal acumen, and business insight, we tackle with precision the unique industry challenges our clients face.

Patent Litigation

When our clients' patent rights are violated or challenged, we mobilize our nationwide team of trial attorneys to advocate for their innovations in court. Over the past decade, we have tried more than 250 cases in federal and state courts, as well as before the ITC, PTAB, and United States Court of Appeals for the Federal Circuit (CAFC).

Clients frequently call on us to assume lead trial counsel roles in high-stakes litigation, especially when the legal or factual circumstances are not in their favor. Our ability to develop creative solutions and compelling arguments has earned us a strong track record in precedent-setting cases.

Hatch-Waxman & Life Sciences Litigation

We defend our clients' interests in the highly competitive pharmaceutical, biotechnology, and medical device industries, having served as lead trial counsel in hundreds of abbreviated new drug application (ANDA) cases over the past decade.

Advising both branded and generic drug companies, we represent clients in Hatch-Waxman and ANDA litigation, as well as on patent and noticing provisions related to the Biologics Price Competition and Innovation Act (BPCIA).

Our counseling services include pre-litigation strategies and guidance on interpartes review (IPR) petitions to assist in the selection, development, approval, and marketing of pharmaceuticals, technologies, and therapies.

FDA & Regulatory

As manufacturers navigate an evolving regulatory landscape, they need legal counsel with deep experience before the FDA to secure market entry and protect marketing exclusivity rights.

We advise clients throughout the entire product life cycle – from development and approval to marketing – across a wide range of FDA-regulated products, including brand and generic drugs, biologics, biosimilars, human tissue and stem cell products, medical devices, food, and dietary supplements. Our team also represents clients in patent licensing and antitrust-related FDA disputes.

International Trade Commission

Our skilled IP trial attorneys are well versed in the complexities of ITC Section 337 investigations, which offer a powerful tool to block infringing products from entering the U.S. market, despite the absence of monetary damage awards.

We have a strong track record representing clients across industries such as mobile devices, semiconductors, and chemical compounds. Our team combines years of legal and technical expertise to navigate these fast-paced cases, leveraging a deep understanding of ITC procedures and the role of the Office of Unfair Import Investigations (OUII).

Patent Trial & Appeal Board

Since the United States Patent and Trademark Office (USPTO) established the PTAB in 2012, we have secured numerous favorable outcomes for our clients. Many of our attorneys are registered to practice before the USPTO and hold advanced technical degrees, enabling us to challenge industry experts and lead IPR, covered business method (CBM) review, and postgrant review (PGR) proceedings.

As petitioner's counsel, we strategically file IPR petitions to negotiate favorable settlement agreements and secure stays in pending district court litigations. Our success includes advancing petitions to final written decisions that invalidated all patent claims, including those involving over 100 claims.

Trade Secrets Litigation

When trade secret misappropriation disputes arise, our experienced trial team employs aggressive litigation strategies to assert or defend claims in state and federal court, and before the ITC.

In instances of theft, we deliver a rapid, decisive response to mitigate damage, recover losses, and secure emergency remedies like restraining orders and injunctions. On the defense, we proactively challenge broad accusations, focusing on whether the information is truly secret and adequately protected.

Prevention is essential for protecting corporate trade secrets. In advance of disputes, we collaborate with clients to develop and implement safeguards that minimize risk and prevent litigation.

Insights

Event | October 30, 2024

Kisaco Research Pharma and Biotech Patent Litigation 2024

On October 30, Axinn partner Matthew Murphy will speak on "The Global Application of Skinny Labeling and Second Medical Uses" at Kisaco Research's Pharma and Biotech Patent Litigation Conference, being held October 29-30.

EDTX Bench Bar Conference 2024

Axinn is pleased to announce its sponsorship of the Eastern District of Texas Bar Association's Bench Bar Conference being held October 23-25 in Plano, Texas.

Event | October 22, 2024

AIPLA IP Practice in Japan Committee Pre-Meeting and Dinner 2024

Axinn is proud to sponsor the AIPLA IP Practice in Japan Committee Pre-Meeting and Dinner, being held October 22-23 in National Harbor, Maryland.

October 20, 2024 | 3 min read

Apportionment of Trade Secret Damages: Will Phillips 66 Ask A Six Hundred Million Dollar Question?

In a trade secret misappropriation action, a complainant is required to prove the amount of its damages with reasonable certainty and that this amount has been caused by the misappropriation. Therefore, the trade secret owner should be prepared to explain how its claimed or awarded damages are sufficiently apportioned to the trade secrets alleged or found to have been misappropriated. Easy to say in principle, harder to execute in real life.

Event | October 15, 2024

LSPN North America Fall Conference 2024

On October 15, Axinn partner Jason Murata will speak on the "Intersectionality of Intellectual Property with Licensing and Commercialization" panel at Life Sciences Patent Network's North America Fall Conference, being held October 15-16 in San Francisco.

ACI 4th Annual Passport to Proficiency on the Essentials of Hatch-Waxman and BPCIA

On October 8, Axinn partner Jason Murata will speak on the "Key Agencies Overview: Understanding the Jurisdiction and Interplay of the FDA and the USPTO in the Patenting of Drugs, Biologics and Biosimilars" panel at American Conference Institute's Hatch-Waxman and BPCIA Proficiency Series, being held virtually October 8–24.

News | October 4, 2024 | 1 min read

Jason Murata Named a 2024 Diversity Champion Award Recipient by the American Intellectual Property Law Association

Axinn partner Jason Murata was named a 2024 Diversity Champion Award Recipient by the American Intellectual Property Law Association (AIPLA).

News | October 3, 2024 | 1 min read

Axinn Partners Ranked in the 2025 Edition of Benchmark Litigation

Axinn partners Rachel Adcox, Matt Becker, Aziz Burgy, Ted Mathias, Denise Plunkett, Thomas Rohback, and Jeannine Sano were selected as "Litigation Stars" for the 2025 Edition of Benchmark Litigation. Partner Craig Reiser was selected as "Future Star." In addition, Axinn is ranked as a "Recommended Firm" in Connecticut and ranked in tier two for intellectual property.

CCWC 20th Annual Career Strategies Conference

On October 2, Axinn partners Leslie Overton and Jeannine Sano will speak at Corporate Counsel Women of Color's Career Strategies Conference, being held October 2-5 in Las Vegas.

Event | October 1, 2024

Pro Bono Partnership 27th Anniversary Gala

On October 1, Axinn sponsored Pro Bono Partnership's 27th Anniversary Gala.

Practice Chair



Matthew J. Becker

Featured Insights

- Stakeholders 24th Annual CYOC Career Development Conference SPONSORSHIP
- CompLaw 33rd Annual Advanced EU Brussels Conference SPEAKING ENGAGEMENT
- ALM General Counsel Conference East 2024
 SPEAKING ENGAGEMENT ANTITRUST
- Navigating Global Politics: The Future of Antitrust Merger Policy and Foreign Direct

Investment (FDI)

WEBINAR ANTITRUST

- Global Legal Group Global Class Actions Symposium 2024
 SPEAKING ENGAGEMENT LITIGATION & TRIALS
- NAPABA Convention 2024 sponsorship
- Kisaco Research Pharma and Biotech Patent Litigation 2024
 SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY
- Lighthouse Litigator's Roundtable Series SPEAKING ENGAGEMENT LITIGATION & TRIALS
- AIJA IP/TMT Seminar // 11th Antitrust Annual Conference
 SPEAKING ENGAGEMENT ANTITRUST
- EDTX Bench Bar Conference 2024
 SPONSORSHIP ANTITRUST

© 2024 Axinn, Veltrop & Harkrider LLP. All Rights Reserved